In the meantime current gene therapies remain expensive and challenging to scale up because each patient’s batch of cells has ...

Improving sickle cell care by expanding treatment options, advancing new therapies and amplifying the voices of people with ...

Vertex said sickle cell patients had not yet received infusions of its gene therapy Casgevy. That’s now changed, as the ...

Kendric Cromer, 12, is among the first patients to be treated with gene therapy just approved by the F.D.A. that many other ...

It’s been almost a year since the Food and Drug Administration approved the first genetic treatments for sickle cell disease.

CRISPR Therapeutics developed a gene-editing medicine called Casgevy in collaboration with Vertex Pharmaceuticals. This therapy treats two blood-related disorders: sickle cell disease (SCD ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $508.38, a high estimate of ...

a breakthrough treatment for people with sickle cell disease. The new medicine was developed by Boston-based Vertex ...

Vertex Pharmaceuticals (NASDAQ ... The commercialization of gene-editing therapy Casgevy as a one-time treatment for sickle cell disease and transfusion-dependent beta-thalassemia is in the ...